1 – 10 of 99
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Pharmaceutical Industry Payments to Patient Organizations in Poland : Analysis of the Patterns, Evolution, and Structure of Connections
2025) In International journal of social determinants of health and health services 55(2). p.199-212(
- Contribution to journal › Article
-
Mark
Unknowns of drug company payment disclosure : why the UK needs payment transparency legislation
2025) In BMJ Evidence-Based Medicine(
- Contribution to journal › Article
-
Mark
Results reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed
(
- Contribution to journal › Article
-
Mark
Self-regulation of UK's pharmaceutical industry
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Det är dags att Läkartidningen slutar med läkemedelsannonser
2025) In Läkartidningen(
- Contribution to journal › Debate/Note/Editorial
- 2024
-
Mark
Race in clinical trials in Sweden: how regulatory and medical standards in clinical research trump the post-racial discourse
(
- Contribution to journal › Article
-
Mark
“Black race”, “Schwarze Hautfarbe”, “Origine africaine”, or “Etnia nera”? The absent presence of race in European pharmaceutical regulation
(
- Contribution to journal › Article
-
Mark
Delays in dealing with complaints against drug companies are growing, BMJ finds
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Aligning digital biomarker definitions in psychiatry with the National Institute of Mental Health Research Domain Criteria framework
(
- Contribution to journal › Article
-
Mark
Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015 and 2019 : A content analysis
(
- Contribution to journal › Article